This virus-like particle (VLP) formulation of full-length human CCR6 (amino acids 1-374) is expressed in mammalian cells with a C-terminal 10×His tag, preserving native receptor conformation and membrane protein topology. The recombinant CCR6 protein demonstrates high purity (>90% by SEC-HPLC) and low endotoxin levels (<1.0 EU/μg, LAL method), meeting rigorous standards for functional studies. Validated via ELISA, it exhibits specific binding to anti-CCR6 antibody (CSB-RA004845MA1HU) (EC50: 44.79–56.10 ng/mL at 10 μg/mL immobilization), with VLPs (CSB-MP3838) serving as negative controls to confirm assay specificity. Mammalian expression ensures proper glycosylation and structural integrity, which are critical for CCR6's role in chemokine signaling and immune cell migration. The VLP format mimics natural receptor clustering, enhancing antigen presentation for antibody development. Lyophilized for stability, this CCR6 protein enables research into inflammatory diseases, T-cell trafficking, and therapeutic targeting of CCR6-mediated pathways in autoimmunity and cancer.
The CCR6 protein is a receptor belonging to the beta chemokine receptor family and is classified as a G protein-coupled receptor (GPCR). It is primarily expressed in various immune cell types, notably immature dendritic cells and memory T cells, suggesting its integral role in the immune system's function and regulation [1]. CCR6-CCL20 interaction is crucial for guiding the migration of CCR6-expressing cells to sites of inflammation and tissue damage, thereby facilitating immune responses [2][3].
CCR6 is also involved in various inflammatory and homeostatic processes. It is particularly significant in conditions such as inflammatory bowel disease (IBD), rheumatoid arthritis, and certain forms of cancer [2][4][5]. The receptor is expressed by various T cell subsets, including Th17 cells, which are pivotal in the development of autoimmune conditions, and Tregs, which contribute to maintaining immune tolerance [6][7][8]. Moreover, CCR6 expression on memory B cells is essential for their migration to antigen-rich areas in lymphoid tissues, highlighting its importance in immunologic memory [9][10].
The relevance of the CCR6-CCL20 axis extends to its implications in cancer biology. Elevated levels of CCR6 and its ligand CCL20 have been observed in numerous malignancies, including colorectal and lung cancers, where they appear to promote tumor growth and metastasis [4][5][11]. The mechanism often involves the recruitment of regulatory T cells and other immune cells to the tumor microenvironment, which can enhance tumor development and progression [12][13]. This cancer-related signaling indicates a dual role for CCR6, as it can function in anti-tumor immunity through T cell recruitment while simultaneously participating in processes that favor tumor progression through immune evasion mechanisms [14][15].
References:
[1] D. Sano, M. Tazawa, et al. Selection of cellular genetic markers for the detection of infectious poliovirus. Journal of Applied Microbiology, vol. 124, no. 4, p. 1001-1007, 2018. https://doi.org/10.1111/jam.13621
[2] J. Ryu, M. Park, B. Kim, K. Ryu, & S. Woo. Tonsil-derived mesenchymal stromal cells produce cxcr2-binding chemokines and acquire follicular dendritic cell-like phenotypes under tlr3 stimulation. Cytokine, vol. 73, no. 2, p. 225-235, 2015. https://doi.org/10.1016/j.cyto.2015.02.028
[3] J. Liu, X. Zheng, et al. Expression of ccr6 in esophageal squamous cell carcinoma and its effects on epithelial-to-mesenchymal transition. Oncotarget, vol. 8, no. 70, p. 115244-115253, 2017. https://doi.org/10.18632/oncotarget.23318
[4] T. Ito, W. Carson, K. Cavassani, J. Connett, & S. Kunkel. Ccr6 as a mediator of immunity in the lung and gut. Experimental Cell Research, vol. 317, no. 5, p. 613-619, 2011. https://doi.org/10.1016/j.yexcr.2010.12.018
[5] S. Gómez-Melero, F. Garcı́a-Maceira, et al. Development of a high-throughput calcium mobilization assay for ccr6 receptor coupled to hydrolase activity readout. Biomedicines, vol. 10, no. 2, p. 422, 2022. https://doi.org/10.3390/biomedicines10020422
[6] X. Zhang, Z. Hu, A. Meng, G. Duan, Q. Zhao, & J. Yang. Role of ccl20/ccr6 and the erk signaling pathway in lung adenocarcinoma. Oncology Letters, 2017. https://doi.org/10.3892/ol.2017.7253
[7] L. Rivino, P. Gruarin, et al. Ccr6 is expressed on an il-10–producing, autoreactive memory t cell population with context-dependent regulatory function. The Journal of Experimental Medicine, vol. 207, no. 3, p. 565-577, 2010. https://doi.org/10.1084/jem.20091021
[8] M. Bonelli, A. Puchner, et al. Ccr6 controls autoimmune but not innate immunity‐driven experimental arthritis. Journal of Cellular and Molecular Medicine, vol. 22, no. 11, p. 5278-5285, 2018. https://doi.org/10.1111/jcmm.13783
[9] V. Wacleche, J. Goulet, et al. New insights into the heterogeneity of th17 subsets contributing to hiv-1 persistence during antiretroviral therapy. Retrovirology, vol. 13, no. 1, 2016. https://doi.org/10.1186/s12977-016-0293-6
[10] R. Elgueta, E. Marks, et al. Ccr6-dependent positioning of memory b cells is essential for their ability to mount a recall response to antigen. The Journal of Immunology, vol. 194, no. 2, p. 505-513, 2015. https://doi.org/10.4049/jimmunol.1401553
[11] S. Lee, K. Park, et al. Human antigen r-regulated ccl20 contributes to osteolytic breast cancer bone metastasis. Scientific Reports, vol. 7, no. 1, 2017. https://doi.org/10.1038/s41598-017-09040-4
[12] M. Shigeoka, Y. Koma, T. Kodama, M. Nishio, M. Akashi, & H. Yokozaki. Tongue cancer cell-derived ccl20 induced by interaction with macrophages promotes cd163 expression on macrophages. Frontiers in Oncology, vol. 11, 2021. https://doi.org/10.3389/fonc.2021.667174
[13] K. Chen, S. Lin, et al. Selective recruitment of regulatory t cell through ccr6-ccl20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. Plos One, vol. 6, no. 9, p. e24671, 2011. https://doi.org/10.1371/journal.pone.0024671
[14] M. García, M. Navarrete-Muñoz, et al. Cd32 expression is not associated to hiv-dna content in cd4 cell subsets of individuals with different levels of hiv control. Scientific Reports, vol. 8, no. 1, 2018. https://doi.org/10.1038/s41598-018-33749-5
[15] E. Kwon, H. Cha, & H. Lee. Systematic omics analysis identifies ccr6 as a therapeutic target to overcome cancer resistance to egfr inhibitors. Iscience, vol. 27, no. 4, p. 109448, 2024. https://doi.org/10.1016/j.isci.2024.109448
